Media Release

Rotkreuz, 21 June 2011

15 years of growth above the market

The Roche Diagnostics Division is celebrating the 15th anniversary of its Elecsys® platform, the company’s key driver in immunochemistry. Elecsys continually sets new standards in immunodiagnostics and is incorporated into the cobas® modular platform with 30,000 systems produced since 1996. Today, Elecsys is the market leading technology for heterogeneous immunoassays.

Elecsys® is one of the most important business drivers in the Roche Diagnostics division. The revenue from immunochemistry reached 1.957 billion Swiss Francs showing an impressing growth rate of 16.7 % in 2010. "Obviously, we will celebrate this special occasion," said Daniel Jaquemar, International Business Leader for the cobas 4000 analyzer series at Roche Professional Diagnostics (RPD). "Our customers run 1 billion Elecsys tests per year, an average of 30 tests per second. Such success stories are very unusual in our business. And the prospects for further growth in our immunodiagnostic business remain excellent – thanks to Elecsys."

At the heart of the technology

At the core of Elecsys is the Electrochemoluminescence (ECL) detection technology with unparalleled properties for clinical efficiency and medical benefit to improve personalized therapeutic regimes. The ECL innovation was acquired by Roche and then co-developed with its partner Hitachi specifically for the in-vitro diagnostics market: "Looking back, we can say that the decision to acquire and develop ECL was absolutely right," says Thomas Hartke, Senior International Product Manager for the cobas 6000 analyzer series and the cobas 8000 modular analyzer series at RPD. "Thanks to ECL, the cobas modular platform is one of the fastest and most reliable serum work area platforms in the market today – and thus one of the pillars of our business."

The importance of the ECL technology is also shown by the fact that today it is a central component of all its cobas serum work area platforms. The cobas e modules are an integral part of the cobas 4000 and, cobas 6000 analyzer series and of the cobas 8000 modular analyzer series. Last fall, RPD launched its new cobas e 602 immunoassay module, which completes the cobas 8000 modular analyzer series for high throughput needs.

Broad spectrum of tests

The full Elecsys menu comprises more than 90 immunoassay tests for cardiac and infectious diseases, maternal care, thyroid, and tumor markers, to mention but a few. "This wide range of tests is unique to the market - and every year new assays are added," says Dusanka Kasapic, Senior International Product Manager Immunochemistry Reagents at RPD. "On top of the reliability and speed of the cobas e modules, our test portfolio is a key selling point for our cobas modular platform – and certainly one reason why we have continued to increase our market share in the past few years and achieved exceptional growth for 15 years now."

And all interviewees are convinced that this growth will continue in the future: "Elecsys is still a very future- proof platform," said Jaquemar. "Elecsys has now developed an almost legendary reputation. The combination of reliable automation, excellent assay performance, and the wide range of tests is unique – and promises at least another fifteen years of success!”

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.